SAVA Share Price | Cassava Sciences, Inc. Stock Analysis & Recommendation

Q: How big is Cassava Sciences, Inc.?

Market Cap: As of Jun 18, Cassava Sciences, Inc. has a market capitalization of 100.00 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -72.78 million.Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 145.70 million and total assets of 157.53 million.

Q: What does Cassava Sciences, Inc. do?

Overview:Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nervous system disorders, specifically targeting neurodegenerative diseases such as Alzheimer’s. It operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) Market cap: USD 100.00 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.92 Return on Equity: -113.49% Price to Book: 0.78 Contact Details:Address: 7801 N Capital of Texas Hwy Ste 260, AUSTIN TX: 78731-1192 Tel: 1 512 5012444 Website: https://www.cassavasciences.com/company

Q: Is Cassava Sciences, Inc. technically bullish or bearish?

As of 28 July 2025, the technical trend for Cassava Sciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD shows a mildly bullish signal. The RSI on a monthly basis is bullish, but overall, the mixed signals suggest caution. The stock has significantly underperformed against the S&P 500 over multiple periods, with a 1-year return of -92.45% compared to the S&P 500's 17.14%.

Results Declared: Cassava Sciences, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

505.21 k

Shareholding (Dec 2025)

FII

9.65%

Held by 65 FIIs

DII

78.76%

Held by 14 DIIs

Promoter

0.00%

How big is Cassava Sciences, Inc.?

22-Jun-2025

As of Jun 18, Cassava Sciences, Inc. has a market capitalization of 100.00 million, with recent quarterly net sales of 0.00 million and a net profit of -72.78 million. As of December 2024, the company reported shareholder's funds of 145.70 million and total assets of 157.53 million.

View full answer

What does Cassava Sciences, Inc. do?

22-Jun-2025

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s. It has a market cap of $100 million and reported a net profit loss of $23 million as of March 2025.

View full answer

Who are in the management team of Cassava Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Cassava Sciences, Inc. includes Mr. Remi Barbier as Chairman, President, and CEO, and Dr. Nadav Friedmann as Chief Medical and Operating Officer. The Board of Directors also features independent members such as Dr. Robert Gussin and Mr. Michael O'Donnell.

View full answer

Is Cassava Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of July 28, 2025, Cassava Sciences, Inc. shows a mildly bearish trend with mixed signals from moving averages and MACD, and has significantly underperformed the S&P 500 with a 1-year return of -92.45%.

View full answer

Compare Cassava Sciences, Inc. with Similar Stocks

Verve Therapeutics, Inc.Adaptive Biotechnologies Corp.Kymera Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 94 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.30

Return on Equity

-129.99%

Price to Book

1.15

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-37.19%

6 Months

-21.83%

1 Year

-35.84%

2 Years

-91.59%

3 Years

-93.2%

4 Years

-95.42%

5 Years

-96.82%

Cassava Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-255.23%

EBIT to Interest (avg)

-80.99

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.92

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.64%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.15

EV to EBIT

0.11

EV to EBITDA

0.11

EV to Capital Employed

0.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

454.17%

ROE (Latest)

-129.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 29 Schemes (11.59%)

Foreign Institutions

Held by 65 Foreign Institutions (9.65%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 54.71% vs -32.06% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.20",
          "val2": "-29.20",
          "chgp": "54.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.50",
          "val2": "-27.60",
          "chgp": "54.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -274.49% vs 75.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-94.50",
          "val2": "-150.20",
          "chgp": "37.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "118.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-91.00",
          "val2": "-24.30",
          "chgp": "-274.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-13.20

-29.20

54.79%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-12.50

-27.60

54.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 54.71% vs -32.06% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-94.50

-150.20

37.08%

Interest

0.00

Exceptional Items

0.00

118.10

-100.00%

Consolidate Net Profit

-91.00

-24.30

-274.49%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -274.49% vs 75.00% in Dec 2024

All Annual Results

Company CV

About Cassava Sciences, Inc.

Cassava Sciences, Inc.

Pharmaceuticals & Biotechnology

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Company Coordinates

Company Details

7801 N Capital of Texas Hwy Ste 260 , AUSTIN TX : 78731-1192

Tel: 1 512 5012444

https://www.cassavasciences.com/company

Registrar Details